30 closest matches · ranked by relevance
Diabetes Mellitus · Cardiovascular Diseases
Primary: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both — 1279; 1318 Participants
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 43; 79 Percentage of patients
Non-small Cell Lung Cancer · Lung Cancer · Advanced Malignancies
Primary: Progression-free Survival (PFS) — 24.016; 11.072; 16.821 months — p=<0.0001
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
Acute Lymphocytic Leukemia
Primary: Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years — 64.9 percentage of participants
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
Pediatric Acute Lymphoblastic Leukemia · Leukemia · Acute Lymphoblastic Leukemia
Primary: Enrollment Rate of Participants — 25 Participants
MDS
Primary: Percentage of Participants With Overall Survival (OS) — 47.9; 26.6 percentage of participants — p=0.0001
Non-Small Cell Lung Cancer
Primary: Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only — 35; 11; 43; 29 Participants
Cervical Intraepithelial Neoplasia
Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Patent Ductus Arteriosus
Primary: Safety Endpoint: The Rate of Major Complications After an Attempted ADO II AS Device Implant — 0; 2.8 percentage of participants
FIGO Stage III and IV Ovarian Cancer · FIGO Stage III and IV Fallopian Tube Cancer · FIGO Stage III Primary Peritoneal Cancer
Primary: Progression Free Survival — 50; 100 Percentage of PFS
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Leukemia, Lymphocytic, Acute
Primary: Complete Response (CR) Rate — 28 percentage of participants
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Acute Lymphoblastic Leukemia · Lymphoblastic Leukemia
Primary: Response Rate During the First Course of JZP-458 Administration — 18; 70; 44; 20 Participants
Liver Diseases · Hepatocellular Cancer · Endstage Liver Disease
Primary: Living Donor Pain Management — 2.62; 2.56; 2.87; 2.67 Scores on Visual Analogue Pain Scale
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 69 Participants
Heart Failure
Primary: Percentage of Patients Free From Lead, Delivery System and Implant Related Complications. — 82.2 percentage of patients
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Atrial Fibrillation
Primary: Number of Subjects That Achieved Freedom From AF/AFL/AT (Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia) With or Without the Use of Anti-arrhythmic Drugs After a…
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Avascular Necrosis · Osteoarthritis, Hip · Inflammatory Arthritis
Primary: Survival of the Implant System — 89 participants
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99
Allergic Conjunctivitis
Primary: Subject-reported Ocular Itching Score — 52.003; 60.040; 74.657 units on a scale*minutes
Acute Lymphoblastic Leukemia
Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants
B Precursor Type Acute Leukemia
Primary: Fat Mass — 5.1; 10.7 percent change in fat mass